

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/086358 A1

- (51) International Patent Classification⁷: **A61K 9/16**
- (21) International Application Number: PCT/EP02/04207
- (22) International Filing Date: 12 April 2002 (12.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicant (*for all designated States except US*): **CAMP-INA B.V.** [NL/NL]; Hogeweg 9, NL-5301 LB Zaltbommel (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **ELLISON, Mark, Jason, Heath** [GB/NL]; Jan Heinstraat 2a, NL-5211 TD 's Hertogenbosch (NL). **LAMBREGTS-VAN DEN HURK, Theodora, Antonia, Maria** [NL/NL]; Generaal v. Vlijmenstraat 5, NL-5463 CH Veghel (NL).
- (74) Agent: **VAN SOMEREN, Petronella, Francisca, Hendrika, Maria**; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *with international search report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: EXCIPIENT FOR USE IN DRY POWDER INHALATION PREPARATIONS

(57) Abstract: The present invention relates to an excipient for dry powder inhalation preparations comprising granules made of primary carrier material, which granules break down during inhalation in such a manner that they give a concentration of primary carrier material at stage 2 of the twin stage impinger determined by the antrone reaction of at least 5%. Such excipients are for example obtainable by granulating a primary carrier material in a fluid binding agent and drying the granules thus obtained. The invention further relates to a method of preparing the excipient, to the use of the excipient and to dry powder inhalation preparations comprising the excipient.



WO 03/086358 A1

EXCIPIENT FOR USE IN DRY POWDER INHALATION PREPARATIONS

The present invention relates to an excipient for use in dry powder inhalation preparations. The invention
5 furthermore relates to dry powder inhalation preparations containing the excipient, to a method for making the excipient and to an excipient made of lactose.

The delivery of active molecules to the lungs can be achieved using metered dose inhalers (MDI), dry powder
10 inhalers (DPI) or nebulisers. In the current market MDI are dominant with DPI a distant second and nebulisers further back. MDI have continued to be successful despite the difficulty of co-ordinating actuation with inhalation and the extensive deposition on the back of the oropharynx due to the
15 high velocity of the droplets.

However, this success has been blighted in recent times by the environmental concerns over chlorofluorocarbons (CFCs), which have been used as propellants. The Montreal
20 protocol in 1989 detailed the need to replace CFC propellants, because of their contribution to ozone depletion. This has resulted in the development of propellants which do not deplete ozone and an increase in activity in the DPI field.

There are a number of DPI products available on the
25 market today, using many different technological approaches for delivering an active component to the lungs. To penetrate into the target areas of the lungs, active molecules must possess an aerodynamic particle size of less than 5µm. This is achieved primarily by micronisation. The particles
30 produced are, however, inherently cohesive/adhesive in nature due to an excess of surface free energy. The surface properties generated in manufacture can lead to adherence to the device and/or the formation of stable agglomerates, both

of which can have a negative influence on the dose reproducibility as they are uncontrollable.

Therefore, traditionally a DPI product consists of the device, the active component and an inert carrier (i.e. excipient) with the purpose to aid flow and encourage dispersion. The active particles adhere to the surface of the carrier, ideally preventing segregation but allowing detachment during inhalation.

The preferred carrier material has always been α -lactose monohydrate. The reasons for this include the fulfillment of the carrier functions by improving flow, the availability of toxicological information and its relatively low price. The manipulation of lactose to balance the requirements of high and constant deposition values and good flow properties has focused primarily on the particle size distribution. However, a number of other techniques have been investigated to improve the performance of lactose as a carrier.

US patent 5,254,330 describes the use of smooth crystals produced by controlled crystallization, which have a rugosity of less than 1.75.

An alternative to alpha-lactose monohydrate is described in the International patent WO98/50015, which makes use of roller dried anhydrous lactose with a size between 50 and 250 μm and a rugosity between 1.9 and 2.4.

The lactose described in the prior art is in a crystalline form. The particle size is relatively small. It was found that the deposition of these known particles can be further improved.

It is known that decreasing the carrier particle size of a powder mixture, results in an increase in the fine particle fraction. As the particle size is reduced the relationship between the carrier lactose particle and

micronised active component changes. For large carrier particles the active adheres to the surface of the carrier. As carrier size decreases and approaches that of the micronised active component the relationship is more of a weak agglomerate, which can be easily dispersed especially with the modern inhaler devices.

However, as the carrier particle size is decreased, so are the flow properties which affects the distribution of the active component within the mix and the dose reproducibility.

It is the object of the present invention to provide an excipient that can be used as a carrier in dry powder inhalation preparations and that consists of particles large enough to have suitable flow properties and a structure to promote dispersion.

This object is achieved by an excipient for dry powder inhalation preparations comprising granules made of primary carrier material, which granules break up during inhalation in such a manner that they give a concentration of primary carrier material on stage 2 of the twin stage impinger (e.g. by Erweka, UK) determined by the antrone reaction of at least 5%.

Preferably, the concentration of primary carrier material at stage 2 of the twin stage impinger determined by the antrone reaction is at least 10%, more preferably at least 20%.

Such an excipient is obtainable by granulating a primary carrier material in a fluid binding agent, for example in a fluid bed dryer or a shear mixer, and drying the granules thus obtained. The fluid binding agent is preferably an aqueous solution of the primary carrier material. Alternatively, the fluid binding agent is a solvent, in particular ethanol. The properties of the excipient granules

may be varied by choosing the fluid binding agent. A solvent will usually evaporate more quickly thus resulting in weaker granules that lead to a higher percentage at stage 2 of the twin stage impinger.

5 The strength of the granules can be manipulated by varying the process parameters such as the amount of fluid binding agent (granulation fluid).

 Weaker granules have the structure which promotes dispersion of the active component, as they will break down
10 as they pass through an inhaler.

 Drying the granules can be performed in various manners. In general, it was found that the quicker the drying operation, the weaker the granules. Suitable drying means are for example formed by an oven. Especially preferred is drying
15 while the granules are kept in motion, such as in a fluid bed dryer.

 The particle size of the granules that (alone or in combination with some other vehicle) form the excipient lies between 50-1000 μm . Preferably, the particle size of the
20 granules lies between 200-500 μm . The primary particle median geometric size of the granules lies in the range 1-170 μm , preferably in the range 1-15 μm .

 The primary carrier material can be selected from a wide variety of materials which are preferably known to be
25 suitable for DPI, including monosaccharides, such as glucose, fructose, mannose; polyols derived from these monosaccharides, such as sorbitol, mannitol or their monohydrates; disaccharides, such as lactose, maltose, sucrose, polyols derived from these disaccharides, such as
30 lactitol, mannitol, or their monohydrates; oligo or polysaccharides, such as dextrans and starches.

 Preferably the primary carrier material is a crystalline sugar such as glucose, lactose, fructose,

mannitol or sucrose because such sugars are both inactive and safe. Most preferably, lactose is used.

The invention furthermore relates to a dry powder inhalation formulation which contains a pharmacologically active component and an excipient as claimed for delivery of the active component to the lungs.

The active component is for example selected from the group consisting of steroids, bronchodilators, cromoglycate, proteins, peptides and mucolytics, or from the group consisting of hypnotics, sedatives, analgesics, anti-inflammatory agents, anti-histamines, anti-convulsants, muscle relaxants, anti-spasmodics, anti-bacterials, antibiotics, cardiovascular agents, hypoglycaemic agents.

According to a further aspect thereof, the invention relates to a method for producing an excipient as claimed, comprising granulating a primary carrier material in a fluid binding agent and drying the granules thus obtained. The same preferred process parameters apply as indicated above.

The invention in a preferred embodiment thereof relates to lactose granules for use in dry powder inhalation preparations, which granules break down during inhalation in such a manner that they give a concentration of primary carrier material at stage 2 of the twin stage impinger determined by the antrone reaction of at least 5%, preferably at least 10%, more preferably at least 20%. These granules are obtainable by granulating lactose in a lactose solution or a solvent, such as ethanol, and drying the granules thus obtained. The active component is added to the finished granules.

The present invention is further illustrated in the example that follows.

EXAMPLE

To demonstrate the concept of the present invention, granules with a particle size distribution of 200-500µm were produced from α-lactose monohydrate (DMV International, the Netherlands) with a particle size distribution of 2-16µm. A medium shear mixer (Kenwood) was used to granulate 450 g of lactose using an aqueous lactose solution, water or ethanol as the binding agent, added using a peristaltic pump (LKB). The mass was passed through a 1 mm screen (Erweka) and then dried in a fluid bed dryer (Aeromatic) or tray oven (Heraeus). The 200-500 µm fraction was prepared by screening with a sieve shaker (Retsch).

The batches were as summarized in Table 1.

Table 1

Batch	Quantity fluid binding agent (w/w)	Lactose concentration in fluid binding agent (w/w)	Mixing time (minutes)	Drying
1	14%	5%	4	Oven
2	14%	5%	4	Fluid bed
3	14%	5%	3	Fluid bed
4	29%	Ethanol (no lactose)	5	Oven
5	20%	5%	4	Fluid bed
6	14%	0%	3	Fluid bed
7	14%	50%	3	Fluid bed

Determining the quantity of lactose on stage 2 by means of the antrone test is performed as follows. The antrone solution is prepared by dissolving 200 mg antrone in 200 g sulphuric acid. 1 ml of sample deposited at stage 2 of the impinger is collected and added to 2 ml of antrone solution. This mixture is allowed to stand for one hour. Subsequently the UV absorbance at 625 nm is determined. The result is given in the following table. The fine particle fraction (FPF) is the active component (e.g. the drug) reaching stage 2 (Table 2), determined as described hereinbelow.

Table 2

% Fine Particle Fraction (%FPF) represented by stage 2

Batch no.	% lactose stage 2	%Fine Particle Fraction (%FPF)
1	1	29.1
2	5	45.8
3	9	51.6
4	24	61.0
5	2	38.6
6	6	48.1
7	8	50.1
Reference (DCL 15)	0	31.2

The granules were blended with the drug sodium cromoglycate (1.8% (w/w)). On completion of the mixing process it was clearly evident that the granules had maintained their initial shape. The formulations were assessed in vitro using the twin stage impinger at 60 l/min which has a cut off diameter of 6.4 μ m, using the Novolizer

Inhaler (Sofotec). The amount of active component on each stage was determined using UV spectroscopy. (Table 3).

Table 3

5	Batch	Inhaler % active component	Stage 1 % active component	Stage 2 % active component (=FPF)	CU (%) (%RSD)
	1	13.5	66.7	29.1	97.7 (6.8)
	2	13.7	51.8	45.8	92.0 (6.6)
	3	8.8	40.3	51.6	96.2 (2.7)
10	4	7.7	23.8	61.0	97.8 (3.4)
	5	16.8	50.2	38.6	94.6 (6.7)
	6	10	43.4	48.1	96.2 (4.4)
15	7	9.5	36.9	50.1	97.7 (1.7)
	Reference	15.8	59.7	31.2	97.2 (4.6)

20 Table 3 shows the in vitro deposition values for the 8
 batches of granules (7 according to the invention and 1
 reference (DCL 15 from DMV International, the Netherlands)),
 detailing recovery of active component from the inhaler,
 stage 1, stage 2 (FPF), content uniformity (CU) and relative
 25 standard deviation (%RSD).

Granulation is determined by distribution of
 liquid over the surface of particles, forming liquid bridges
 between particles. This is followed by the evaporation of the

liquid resulting in the formation of solid bridges which binds particles together forming granules.

From the results of this experiment it can be derived that decreasing the amount of liquid available for dispersion in granulation, reduces the amount of potential solid bridges producing weaker granules (batch nos. 5 and 2).

Poor dispersion of liquid as a result of shorter mixing times does also produce weaker granules (batch nos. 2 and 3).

Furthermore, it was found that the slower the drying rate the larger the crystals, formed during recrystallisation (batch nos. 1, 2 and 4). Fluid bed drying is faster.

Solids concentration in the liquid has no effect due to the relatively good solubility of lactose (batch nos. 3, 6 and 7).

CLAIMS

1. Excipient for dry powder inhalation preparations comprising granules made of primary carrier material, which
5 granules break down during inhalation in such a manner that they give a concentration of primary carrier material at stage 2 of the twin stage impinger determined by the antrone reaction of at least 5%.

2. Excipient as claimed in claim 1, wherein the
10 concentration of primary carrier material at stage 2 of the twin stage impinger determined by the antrone reaction is at least 10%.

3. Excipient as claimed in claim 1 or 2, wherein the concentration of primary carrier material at stage 2 of the
15 twin stage impinger determined by the antrone reaction is at least 20%.

4. Excipient as claimed in claims 1-3, obtainable by granulating a primary carrier material in a fluid binding agent and drying the granules thus obtained.

20 5. Excipient as claimed in claim 4, wherein the fluid binding agent is an aqueous solution of the primary carrier material.

6. Excipient as claimed in claim 4, wherein the fluid binding agent is a solvent, in particular ethanol.

25 7. Excipient as claimed in claim 4, wherein the fluid binding agent is water.

8. Excipient as claimed in claims 4-7, wherein the drying is performed in an oven.

9. Excipient as claimed in claims 4-7, wherein the
30 drying is performed while the granules are kept in motion, such as in a fluid bed dryer.

10. Excipient according to claims 1-9, wherein the particle size of the granules lies between 50-1000µm.

11. Excipient according to claims 1-10, wherein the particle size of the granules lies between 200-500µm.

12. Excipient according to claims 1-11, wherein the primary particle median geometric size of the granules lies
5 in the range 1-170 µm.

13. Excipient according to claims 1-12, wherein the primary particle size median geometric size of the granules lies in the range 1-15 µm.

14. Excipient according to claims 1-13, wherein the
10 primary carrier material is a monosaccharide, such as glucose, fructose, mannose; a polyol derived from these monosaccharides, such as sorbitol, manitol or their monohydrates; a disaccharide, such as lactose, maltose, sucrose, a polyol derived from these disaccharides, such as
15 lactitol, manitol, or their monohydrates; an oligo or polysaccharide, such as dextrans and starches.

15. Excipient according to claims 1-14, wherein the primary carrier material is a crystalline sugar such as glucose, lactose, fructose, manitol or sucrose.

20 16. Excipient according to claim 15, wherein the primary carrier material of the granules is lactose.

17. A dry powder inhalation formulation which contains a pharmacologically active component and an excipient according to claims 1-16, for delivery of the
25 active component to the lungs.

18. A dry powder inhalation formulation according to claim 17, in which the active component is selected from the group consisting of steroids, bronchodilators, cromoglycate, proteins, peptides and mucolytics.

30 19. A dry powder inhalation formulation according to claim 17, in which the active component is selected from the group consisting of hypnotics, sedatives, analgesics, anti-inflammatory agents, anti-histamines, anti-convulsants,

muscle relaxants, anti-spasmodics, anti-bacterials, anti-biotics, cardiovascular agents, hypoglycaemic agents.

20. Method for producing an excipient as claimed in claims 1-17, comprising granulating a primary carrier
5 material in a fluid binding agent and drying the granules thus obtained.

21. Excipient as claimed in claim 20, wherein the fluid binding agent is an aqueous solution of the primary carrier material.

10 22. Excipient as claimed in claim 20, wherein the fluid binding agent is a solvent, in particular ethanol.

23. Excipient as claimed in claim 20, wherein the fluid binding agent is water.

15 24. Excipient as claimed in claims 20-23, wherein the drying is performed in an oven.

25. Excipient as claimed in claims 20-23, wherein the drying is performed while the granules are kept in motion, such as in a fluid bed dryer.

20 26. Lactose granules for use in dry powder inhalation preparations, **characterized in that** the granules break down during inhalation in such a manner that they give a concentration of primary carrier material at stage 2 of the twin stage impinger determined by the antrone reaction of at least 5%, preferably at least 10%, more preferably at least
25 20%.

27. Use of an excipient as claimed in claims 20-25 for the preparation of a dry powder inhalation preparation for the treatment of diseases of the respiratory tract.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/04207

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 750 492 A (GLAXO GROUP LTD) 2 January 1997 (1997-01-02) column 5, line 15-28; example 2 column 3, line 43-55, paragraph 15; claims 1-3	10-25, 27
A	WO 00 53157 A (MUSA ROSSELLA ; VENTURA PAOLO (IT); CHIESI PAOLO (IT); CHIESI FARMA) 14 September 2000 (2000-09-14) the whole document	10-27
A	US 5 738 865 A (STANIFORTH JOHN N ET AL) 14 April 1998 (1998-04-14) column 5, line 30-53 column 10, line 1-67; claims 1-5	10-27

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

*** Special categories of cited documents :**

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

28 January 2003

Date of mailing of the international search report

03/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Uhl, M

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/04207

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 10-25, 27
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 10-25,27

Present claims 1-9, 26 relate to a product defined by reference to the following parameter(s):

"...break down in such a manner that they give a concentration of primary carrier material at stage 2 of the twin stage impinger determined by the antrone reaction of at least 5%"

The use of these parameters in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameters the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the subject matter of claims 10-25 and 27. Claims 1-9 and 26 furthermore relate to a product defined by reference to a desirable characteristic or property, namely that they break down in a certain manner during inhalation and determinable only by the twin stage impinger but to the in this connection unusual antrone reaction.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/04207

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0750492	A	02-01-1997	AT 196989 T	15-11-2000
			AU 2068995 A	03-10-1995
			DE 69519157 D1	23-11-2000
			DE 69519157 T2	09-08-2001
			DK 750492 T3	18-12-2000
			EP 0750492 A1	02-01-1997
			GR 3034845 T3	28-02-2001
			SI 750492 T1	28-02-2001
			US 6183782 B1	06-02-2001
			WO 9524889 A1	21-09-1995
			ES 2152394 T3	01-02-2001
			PT 750492 T	30-03-2001
			ZA 9502049 A	21-12-1995
WO 0053157	A	14-09-2000	WO 0053157 A1	14-09-2000
			AU 3409399 A	28-09-2000
			BR 9917246 A	26-03-2002
			CZ 20013185 A3	16-01-2002
			EP 1158958 A1	05-12-2001
			SK 12482001 A3	07-01-2002
US 5738865	A	14-04-1998	US 5612053 A	18-03-1997
			AU 712369 B2	04-11-1999
			AU 5391796 A	23-10-1996
			CA 2216828 A1	10-10-1996
			EP 0818991 A1	21-01-1998
			HU 9802828 A2	28-07-1999
			JP 11501937 T	16-02-1999
			NO 974404 A	23-09-1997
			NZ 305800 A	26-08-1998
			TW 475903 B	11-02-2002
			US 2002090345 A1	11-07-2002
			WO 9631198 A1	10-10-1996
			US 6387394 B1	14-05-2002